Payment overview · 2025
General Payments
$206.00
13 reported records · 10 companies
Healthcare provider profile · identity verified
Lukose Simon Vadakara, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HAMILTON, NJ · NPI 1255340345
Verified facts
What the public records show
CMS Open Payments records show Lukose Simon Vadakara, MD received $206.00 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Trelegy Ellipta, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.75 | 21.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.78 | 15.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.47 | 9.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.84 | 8.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.55 | 8.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.54 | 8.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.45 | 8.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.22 | 6.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.74 | 6.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.66 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.00 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.75 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 98 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 473 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 443 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 348 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 292 | 103 |
| Gabapentin | Gabapentin | 232 | 77 |
| Eliquis | Apixaban | 224 | 44 |
| Losartan Potassium | Losartan Potassium | 206 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 57 |
| Metformin Hcl | Metformin Hcl | 165 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 77 |
| Omeprazole | Omeprazole | 145 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 49 |
| Furosemide | Furosemide | 130 | 43 |
| Pregabalin | Pregabalin | 128 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 40 |
| Montelukast Sodium | Montelukast Sodium | 122 | 42 |
| Mirtazapine | Mirtazapine | 113 | 35 |
| Finasteride | Finasteride | 103 | 28 |
| Lisinopril | Lisinopril | 103 | 32 |
| Glimepiride | Glimepiride | 102 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 28 |
| Jardiance | Empagliflozin | 98 | 23 |
| Carvedilol | Carvedilol | 97 | 31 |
| Azithromycin | Azithromycin | 93 | 60 |
| Alprazolam | Alprazolam | 91 | 25 |
| Famotidine | Famotidine | 91 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 27 |
| Januvia | Sitagliptin Phosphate | 88 | 23 |
| Potassium Chloride | Potassium Chloride | 88 | 25 |
| Meloxicam | Meloxicam | 87 | 25 |
| Memantine Hcl | Memantine Hcl | 82 | 24 |
| Tramadol Hcl | Tramadol Hcl | 82 | 23 |
| Prednisone | Prednisone | 80 | 43 |
| Valsartan | Valsartan | 79 | 27 |
| Levetiracetam | Levetiracetam | 76 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 18 |
| Farxiga | Dapagliflozin Propanediol | 65 | suppressed |
| Nifedipine Er | Nifedipine | 65 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 52 |
| Linzess | Linaclotide | 63 | 21 |
| Trazodone Hcl | Trazodone Hcl | 62 | 16 |
| Sertraline Hcl | Sertraline Hcl | 60 | 18 |
| Ozempic | Semaglutide | 57 | 16 |
| Torsemide | Torsemide | 57 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 34 |
| Donepezil Hcl | Donepezil Hcl | 54 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 54 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 17 |
| Allopurinol | Allopurinol | 50 | 15 |
| Metformin Hcl Er | Metformin Hcl | 50 | 26 |
| Chlorthalidone | Chlorthalidone | 49 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 20 |
| Celecoxib | Celecoxib | 48 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 11 |
| Xarelto | Rivaroxaban | 48 | 12 |
| Simvastatin | Simvastatin | 46 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 19 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | 12 |
| Atenolol | Atenolol | 35 | 17 |
| Diazepam | Diazepam | 35 | suppressed |
| Lactulose | Lactulose | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 29 |
| Midodrine Hcl | Midodrine Hcl | 35 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 12 |
| Glipizide Er | Glipizide | 34 | 14 |
| Baclofen | Baclofen | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 23 |
| Lubiprostone | Lubiprostone | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Xifaxan | Rifaximin | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Lacosamide | Lacosamide | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | 11 |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 13 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | 12 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 14 |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 19 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 18 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Terbutaline Sulfate | Terbutaline Sulfate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Acetylcysteine | Acetylcysteine | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nucala | Mepolizumab | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Verquvo | Vericiguat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.00 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Cologuard Collection Kit, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error